(12) **Translation of European patent specification**

(11) **NO/EP 3157933 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 498/22 (2006.01) ***C07C 235/80 (2006.01)*** ***C07D 213/82 (2006.01)***
C07C 213/02 (2006.01) ***C07C 237/16 (2006.01)*** ***C07D 309/40 (2006.01)***
C07C 213/10 (2006.01) ***C07C 269/06 (2006.01)*** ***C07D 319/06 (2006.01)***

Norwegian Industrial Property Office

(21)	Translation Published	2019.07.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2019.02.27
(86)	European Application Nr.	15739049.3
(86)	European Filing Date	2015.06.16
(87)	The European Application's Publication Date	2017.04.26
(30)	Priority	2014.06.20, US, 201462015081 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
	Designated Validation States:	MA
(73)	Proprietor	Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA
(72)	Inventor	CHIU, Anna, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA ENQUIST, John, c/o Gilead Sciences Inc.333 Lakeside Drive, CA 94404, USA GRIGGS, Nolan, c/o Gilead Sciences Inc.333 Lakeside Drive, CA 94404, USA HALE, Christopher, c/o Gilead Sciences Inc.333 Lakeside Drive, CA 94404, USA IKEMOTO, Norihiro, c/o J-star Research Inc.3001 Hadley Road Units 1-5A, South Plainfield, NJ 07080, USA KEATON, Katie, Ann, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA KRAFT, Matt, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA LAZERWITH, Scott, E., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA LEEMAN, Michel, c/o Syncom Pharmaceuticals Inc. Kadijk 39747 At., NL-07004 Groningen, Nederland PENG, Zhihui, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA SCHRIER, Kate, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA TRINIDAD, Jonathan, c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA

(72) Inventor
HERPT, Jochem, Van, c/o Syncom Pharmaceuticals Inc. Kadijk 39747 At., NL-07004 Groningen, Nederland
WALTMAN, Andrew, W., c/o Gilead Sciences Inc.333 Lakeside Drive, Foster City, CA 94404, USA

(74) Agent or Attorney
OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge

(54) Title
SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS

(56) References Cited:
EP-A2- 0 456 073, WO-A1-99/25345, WO-A1-2013/087581, WO-A1-00/27823, WO-A1-2010/068262, WO-A1-2014/074675, EP-A1- 2 602 260, WO-A1-2014/100323, EP-A2- 0 378 067, WO-A1-2006/116764, US-A1- 2012 232 117
DAUVERGNE J ET AL: "Synthesis of 4-azacyclopent-2-enones and 5,5-dialkyl-4-azacyclopent-2-enones", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 11, 8 March 2004 (2004-03-08) , pages 2559-2567, XP004492586, ISSN: 0040-4020, DOI: 10.1016/J.TET.2004.01.046
TAO YE ET AL: "Stereoselective synthesis of disubstituted 3(2H)-furanones via catalytic intramolecular C-H insertion reactions of [alpha]-diazo-[beta]-keto esters including asymmetric induction", TETRAHEDRON LETTERS, vol. 35, no. 39, 1 September 1994 (1994-09-01), pages 7269-7272, XP055240254, GB ISSN: 0040-4039, DOI: 10.1016/0040-4039(94)85379-7
ATSUSHI MORI ET AL: "Regioselective Oxygenations of S - Trans Dienes, Silyl Dienol Ethers (SDEs), by Triphenyl Phosphite Ozonide (TPPO) and Its Mechanistic Study", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 66, no. 10, 1 May 2001 (2001-05-01), pages 3548-3553, XP055211589, ISSN: 0022-3263, DOI: 10.1021/jo015562v
WU Y Q ET AL: "Preparation of the pure diastereomeric forms of S- (5'-deoxy-5'-adenosyl)-1-ammonio-4-methyls ulfonio-2- cyclopentene and their evaluation as irreversible inhibitors of S-adenosylmethionine decarboxylase from Escherichia coli", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 1, no. 5, 1 November 1993 (1993-11-01), pages 349-360, XP026615452, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(00)82141-0 [retrieved on 1993-11-01]
"Preparation of methyl 3-(benzyloxy)-5-((2,4- difluorobenzyl)carbamoyl)-1-(2,2-dimethoxy ethyl)-4-oxo- 1,4-dihydropyridine-2-carboxylate An IP.com Prior Art Database Technical Disclosure", , 25 June 2014 (2014-06-25), XP055241733, Retrieved from the Internet: URL:https://priorart.ip.com/IPCOM/00023758 6 [retrieved on 2016-01-15]
ERIK CHORELL- ET AL: "Design and Synthesis of Fluorescent Pilicides and Curlicides: Bioactive Tools to Study Bacterial Virulence Mechanisms", CHEMISTRY - A EUROPEAN JOURNAL., vol. 18, no. 15, 10 April 2012 (2012-04-10), pages 4522-4532, XP055234357, WEINHEIM, DE ISSN: 0947-6539, DOI: 10.1002/chem.201103936
YOSHIFUMI AOKI ET AL: "Dioxanone-Fused Dienes Enable Highly Endo -Selective Intramolecular Diels-Alder Reactions", ORGANIC LETTERS, vol. 17, no. 11, 5 June 2015 (2015-06-05), pages 2756-2759, XP055240130, US ISSN: 1523-7060, DOI: 10.1021/acs.orglett.5b01172
PLAMEN ANGELOV ET AL: "Biomimetic synthesis, antibacterial activity and structure-activity properties of the pyroglutamate core of oxazolomycin", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 10, no. 17, 7 May 2012 (2012-05-07), pages 3472-3485, XP055240194, GB ISSN: 1477-0520, DOI: 10.1039/c2ob00042c
CARA E. BROCKLEHURST ET AL: "Diastereoisomeric Salt Formation and Enzyme-Catalyzed Kinetic Resolution as Complementary Methods for the Chiral Separation of cis -/ trans - Enantiomers of 3-Aminocyclohexanol", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, vol. 15, no. 1, 21 January 2011 (2011-01-21), pages 294-300, XP055241936, US ISSN: 1083-6160, DOI: 10.1021/op1002424
MARK J MULVIHILL ET AL: "Enzymatic resolution of aminocyclopentenols as precursors to D- and L-carbocyclic nucleosides", THE JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 10, 1 January 1998 (1998-01-01), pages 3357-3363, XP002120071, ISSN: 0022-3263, DOI: 10.1021/JO972265A
BARROW J C ET AL: "Preparation and evaluation of 1,3-diaminocyclopentane-linked dihydropyrimidinone derivatives as selective alpha1a-receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 10, no. 17, 1 September 2000 (2000-09-01), pages 1917-1920, XP027377647, ISSN: 0960-894X [retrieved on 2000-09-01]

LLOYD J ET AL: "Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 19, no. 18, 15 September 2009 (2009-09-15), pages 5469-5473, XP026501187, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2009.07.083 [retrieved on 2009-07-22]
ANNA M. GOLDYS ET AL: "Creation through Immobilization: A New Family of High Performance Heterogeneous Bifunctional Iminophosphorane (BIMP) Superbase Organocatalysts", ORGANIC LETTERS, vol. 16, no. 24, 19 December 2014 (2014-12-19), pages 6294-6297, XP055240136, US ISSN: 1523-7060, DOI: 10.1021/ol5029942 -& Anna M Goldys ET AL: "Supplementary Information: Creation Through Immobilization: A New Family of High Performance Heterogeneous Bifunctional Iminophosphorane (BIMP) Superbase Organocatalysts Table of Contents", , 19 December 2014 (2014-12-19), XP055240142, Retrieved from the Internet: URL:http://pubs.acs.org/doi/suppl/10.1021/ ol5029942/suppl_file/ol5029942_si_001.pdf [retrieved on 2016-01-11]
Disclosed Anonymously: "PROCESS FOR THE PREPARATION OF 4H-PYRAN-4-ONE DERIVATIVES", An IP.com Prior Art Database Technical Disclosure, 30 March 2014 (2014-03-30), XP055211363, Retrieved from the Internet: URL:https://priorart.ip.com/IPCOM/00023592 3 [retrieved on 2015-09-04]

Krav

1. Fremgangsmåte for fremstilling av en forbindelse med formel B-1 • J-1 i henhold til følgende skjema:



hvor fremgangsmåten omfatter å reagere den frie syre av B-1 med omtrent en til fem ekvivalenter av J-1; og hvori

Hal er halogen,
n er 1, 2 eller 3, og
R^a er $(C_1\text{-}C_4)$alkyl, $(C_6\text{-}C_{10})$aryl, eller $(C_1\text{-}C_4)$alkyl$(C_6\text{-}C_{10})$aryl.

2. Fremgangsmåte ifølge krav 1, hvori B-1 blir omsatt med J-1 i nærvær av en syre valgt fra gruppen bestående av en uorganisk syre, en organisk syre, en halogenert organisk syre og blandinger derav.

3. Fremgangsmåte ifølge krav 2, hvori syren er valgt fra groupen bestående av saltsyre, hydrobromsyre, hydrojodsyre, trifluormetansulfonsyre, maursyre, trifluoreddiksyre, trikloreddiksyre, perfluorpropionsyre og en blanding derav.

4. Fremgangsmåte ifølge krav 3, hvori syren er trifluoreddiksyre.

5. Fremgangsmåte ifølge et hvilket som helst av kravene 1 til 4, hvor J-1 er i form av et salt eller en co-krystall.

6. Fremgangsmåte ifølge et hvilket som helst av kravene 1 til 5, hvor Hal er F.

7. Fremgangsmåte ifølge et av kravene 1 til 6, hvori J-1 er



.

8. Fremgangsmåte ifølge et av kravene 1 til 6, hvori J-1 er



.

9. Fremgangsmåte ifølge et av kravene 1 til 6, hvori J-1 er



eller



.

10. Fremgangsmåte for fremstilling av et salt med formel B-1 • J-1



B-1 **J-1** **B-1 • J-1**

hvori fremgangsmåten omfatter oppløsning av den frie syre av **B-1** og tilsetning av en ekvivalent av **J-1**, hvori

Hal er halogen,

n er 1, 2 eller 3, og

R^a er $(C_1\text{-}C_4)$alkyl, $(C_6\text{-}C_{10})$aryl, eller $(C_1\text{-}C_4)$alkyl$(C_6\text{-}C_{10})$aryl.

11. Forbindelse som har den følgende strukturen:



12. Fremgangsmåte for fremstilling av en forbindelse med formel C-1



hvor fremgangsmåten omfatter omsetning av en forbindelse med formel B-1 • J-1 med ca. 0,1 til 1 ekvivalent av en egnet syre, og hvori

Hal er halogen, som kan være like eller forskjellige,
n er 1, 2 eller 3, og
R^a er (C_1-C_4)alkyl, (C_6-C_{10})aryl, eller (C_1-C_4)alkyl(C_6-C_{10})aryl.

13. Fremgangsmåte ifølge krav 12, hvori syren er valgt fra gruppen bestående av en uorganisk syre, en organisk syre, en halogenert organisk syre, en Lewis-syre og blandinger derav.

14. Fremgangsmåte ifølge et hvilket som helst av kravene 12 til 13, hvori syren er valgt fra gruppen bestående av saltsyre, hydrobromsyre, hydrojodsyre, trifluormetansulfonsyre, maursyre, trifluoreddiksyre, trikloreddiksyre, perfluorpropionsyre, dikloreddiksyre, kloreddiksyre, eddiksyre, para-toluensulfonsyre, metansulfonsyre, sinkklorid, magnesiumbromid, magnesiumtriflat, kobbertriflat, scandiumtriflat og en blanding derav.

15. Fremgangsmåte ifølge et av kravene 12 til 14, hvori syren er trifluoreddiksyre.